21612468|increased|C0442805^C0205217|start=16|end=25|CONC
21612468|survival|C0038952^C0220921|start=26|end=34|ACTI^CONC
21612468|metastatic prostate cancer|C0936223|start=38|end=64|DISO
21612468|background|C1706907|start=66|end=76|CONC
21612468|biosynthesis|C0005572^C0220781|start=78|end=90|PHEN^CONC
21612468|extragonadal|C2986387|start=94|end=106|CONC
21612468|may|C3812381|start=116|end=119|CONC
21612468|contribute|C1880177|start=120|end=130|ACTI
21612468|progression|C0242656^C0449258|start=138|end=149|DISO^CONC
21612468|castration|C0029189^C0007344|start=153|end=163|PROC
21612468|resistant|C0332325^C2827757|start=164|end=173|PHEN^CONC
21612468|prostate cancer|C0376358^C0600139^C2984325^C3541264|start=174|end=189|DISO^CONC
21612468|evaluated|C0220825|start=194|end=203|PROC
21612468|inhibitor|C1999216|start=236|end=245|CONC
21612468|androgen biosynthesis|C1157302|start=249|end=270|PHYS
21612468|survival|C0038952^C0220921|start=289|end=297|ACTI^CONC
21612468|metastatic|C1522484^C0036525|start=318|end=328|CONC
21612468|castration|C0029189^C0007344|start=329|end=339|PROC
21612468|resistant|C0332325^C2827757|start=340|end=349|PHEN^CONC
21612468|prostate cancer|C0376358^C0600139^C2984325^C3541264|start=350|end=365|DISO^CONC
21612468|received|C1514756|start=375|end=383|CONC
21612468|chemotherapy|C0392920^C3665472^C0013217|start=384|end=396|PROC^CONC
21612468|methods|C0025664^C0449851^C0025663|start=398|end=405|CONC
21612468|assigned|C1552601^C1516050|start=419|end=427|CONC
21612468|ratio|C0456603^C1547037|start=438|end=443|CONC
21612468|received|C1514756|start=478|end=486|CONC
21612468|receive|C1514756|start=500|end=507|CONC
21612468|twice daily|C0585361|start=527|end=538|CONC
21612468|1000|C1883310|start=551|end=555|CONC
21612468|placebo|C0032042^C1706408|start=600|end=607|PROC
21612468|primary|C0205225^C0439631|start=628|end=635|PROC^CONC
21612468|end point|C2349179|start=636|end=645|CONC
21612468|survival|C0038952^C0220921|start=658|end=666|ACTI^CONC
21612468|secondary|C1522484^C0175668^C0205436^C0027627|start=672|end=681|DISO^CONC
21612468|included|C0332257|start=693|end=701|CONC
21612468|time|C0040223^C1548318^C1547403^C3541383|start=702|end=706|CONC
21612468|prostate-specific antigen|C1366489|start=710|end=735|GENE
21612468|psa|C0687688^C1426033^C1417779^C2347427^C3810537^C3813209^C0201544^C1418948^C1366489^C1705954^C1519176^C3272395|start=737|end=740|DISO^PROC^GENE^CONC
21612468|progression|C0242656^C0449258|start=742|end=753|DISO^CONC
21612468|elevation|C0702240^C0439775|start=755|end=764|PROC^CONC
21612468|psa|C0687688^C1426033^C1417779^C2347427^C3810537^C3813209^C0201544^C1418948^C1366489^C1705954^C1519176^C3272395|start=772|end=775|DISO^PROC^GENE^CONC
21612468|level|C0456079^C1547707^C0441889|start=776|end=781|GEOG^CONC
21612468|criteria|C0243161|start=808|end=816|CONC
21612468|progression|C0242656^C0449258|start=819|end=830|DISO^CONC
21612468|free|C1996904^C1880497^C0332296|start=831|end=835|CONC
21612468|survival|C0038952^C0220921|start=836|end=844|ACTI^CONC
21612468|radiologic|C0034599^C0205483|start=858|end=868|OCCU^CONC
21612468|findings|C2607943^C2926606^C3539655|start=869|end=877|PHYS^CONC
21612468|based|C1705938^C1527178|start=878|end=883|CONC
21612468|criteria|C0243161|start=900|end=908|CONC
21612468|psa|C0687688^C1426033^C1417779^C2347427^C3810537^C3813209^C0201544^C1418948^C1366489^C1705954^C1519176^C3272395|start=918|end=921|DISO^PROC^GENE^CONC
21612468|response rate|C0237629|start=922|end=935|CONC
21612468|median|C0876920^C2347635^C2939193^C0549183^C2348144|start=954|end=960|CONC
21612468|follow-up|C1704685^C1522577^C3274571|start=961|end=970|PROC^CONC
21612468|months|C0439231|start=979|end=985|CONC
21612468|survival|C0038952^C0220921|start=995|end=1003|ACTI^CONC
21612468|group|C1552516^C1561557^C1705428^C0441833|start=1053|end=1058|ORGA^CONC
21612468|placebo|C0032042^C1706408|start=1071|end=1078|PROC
21612468|group|C1552516^C1561557^C1705428^C0441833|start=1090|end=1095|ORGA^CONC
21612468|months|C0439231|start=1102|end=1108|CONC
21612468|months|C0439231|start=1118|end=1124|CONC
21612468|hazard ratio|C2985465|start=1126|end=1138|CONC
21612468|confidence interval|C0009667|start=1150|end=1169|CONC
21612468|data|C3245479^C1511726|start=1195|end=1199|DEVI^CONC
21612468|interim|C2827738|start=1222|end=1229|CONC
21612468|analysis|C1524024^C0936012^C0002778|start=1230|end=1238|PROC^CONC
21612468|criteria|C0243161|start=1284|end=1292|CONC
21612468|study|C0947630^C2603343^C0557651^C0008972^C1705923^C1880229|start=1297|end=1302|PROC^OBJC^CONC
21612468|termination|C1549081^C1692758|start=1303|end=1314|CONC
21612468|secondary|C1522484^C0175668^C0205436^C0027627|start=1320|end=1329|DISO^CONC
21612468|including|C0332257|start=1342|end=1351|CONC
21612468|time|C0040223^C1548318^C1547403^C3541383|start=1352|end=1356|CONC
21612468|psa|C0687688^C1426033^C1417779^C2347427^C3810537^C3813209^C0201544^C1418948^C1366489^C1705954^C1519176^C3272395|start=1360|end=1363|DISO^PROC^GENE^CONC
21612468|progression|C0242656^C0449258|start=1364|end=1375|DISO^CONC
21612468|months|C0439231|start=1390|end=1396|CONC
21612468|progression|C0242656^C0449258|start=1408|end=1419|DISO^CONC
21612468|free|C1996904^C1880497^C0332296|start=1420|end=1424|CONC
21612468|survival|C0038952^C0220921|start=1425|end=1433|ACTI^CONC
21612468|months|C0439231|start=1439|end=1445|CONC
21612468|months|C0439231|start=1454|end=1460|CONC
21612468|psa|C0687688^C1426033^C1417779^C2347427^C3810537^C3813209^C0201544^C1418948^C1366489^C1705954^C1519176^C3272395|start=1476|end=1479|DISO^PROC^GENE^CONC
21612468|response rate|C0237629|start=1480|end=1493|CONC
21612468|treatment|C1705169^C0039798^C1533734^C3161471^C1522326^C3538994^C0087111|start=1529|end=1538|PROC^CONC
21612468|group|C1552516^C1561557^C1705428^C0441833|start=1539|end=1544|ORGA^CONC
21612468|related|C1552599^C1704787^C0439849|start=1564|end=1571|CONC
21612468|adverse events|C0877248^C1705413|start=1572|end=1586|DISO^CONC
21612468|including|C0332257|start=1588|end=1597|CONC
21612468|fluid retention|C0268000|start=1598|end=1613|DISO
21612468|hypertension|C0020538|start=1615|end=1627|DISO
21612468|frequently|C0332183|start=1656|end=1666|CONC
21612468|reported|C0684224^C0700287|start=1667|end=1675|PROC^CONC
21612468|group|C1552516^C1561557^C1705428^C0441833|start=1714|end=1719|ORGA^CONC
21612468|placebo|C0032042^C1706408|start=1732|end=1739|PROC
21612468|group|C1552516^C1561557^C1705428^C0441833|start=1751|end=1756|ORGA^CONC
21612468|conclusions|C1707478|start=1758|end=1769|CONC
21612468|inhibition|C0021467^C3463820^C0021469|start=1775|end=1785|PHYS^ACTI
21612468|androgen biosynthesis|C1157302|start=1789|end=1810|PHYS
21612468|prolonged|C0439590|start=1834|end=1843|CONC
21612468|survival|C0038952^C0220921|start=1852|end=1860|ACTI^CONC
21612468|metastatic|C1522484^C0036525|start=1881|end=1891|CONC
21612468|castration|C0029189^C0007344|start=1892|end=1902|PROC
21612468|resistant|C0332325^C2827757|start=1903|end=1912|PHEN^CONC
21612468|prostate cancer|C0376358^C0600139^C2984325^C3541264|start=1913|end=1928|DISO^CONC
21612468|received|C1514756|start=1944|end=1952|CONC
21612468|chemotherapy|C0392920^C3665472^C0013217|start=1953|end=1965|PROC^CONC
21612468|funded|C0016820|start=1968|end=1974|CONC
21612468|biotechnology|C0005574|start=1985|end=1998|OCCU
21612468|gov|C1419208|start=2026|end=2029|GENE
21612468|number|C1554106^C0449788^C0237753|start=2030|end=2036|CONC
